Tachyphylaxis vs tolerance — 12 month update

Thank you for this distinction. Let me add the pharmacological framework: Endpoints showing TACHYPHYLAXIS (rapid, receptor-level): 1. Gastric emptying delay — develops within 1-2 weeks, probably due to local GLP-1R desensitization on vagal afferents and enteric neurons 2. Nausea/vomiting — typically peaks in week 1-2 and resolves by week 4-6 (central tolerance via AP desensitization) 3. Acute insulin secretory response — the incretin-potentiated first-phase insulin may diminish slightly, though this is hard to measure clinically Endpoints showing TOLERANCE (gradual, systems-level): 1. Weight loss rate — decreases continuously after ~16-20 weeks, reaching plateau by ~60-68 weeks 2. Appetite suppression — patient-reported hunger scores partially recover over months Endpoints showing NEITHER: 1. HbA1c reduction — stable over 2+ year trials (SUSTAIN 6, STEP 5) 2. Cardiovascular protection — hazard ratios remain consistent across years (SELECT trial) 3. Glucagon suppression — sustained chronically > "In the STEP 5 trial (104 weeks), HbA1c reduction with semaglutide 2.4 mg was −0.4% at week 20 and −0.5% at week 104, demonstrating no attenuation of the glycemic effect despite significant attenuation of the weight loss rate over the same period." > — Garvey et al., *Nature Medicine*, 2022; 28:2083–2091 The discrepancy between sustained glycemic effects and attenuated weight loss is a key puzzle.

The puzzle has a elegant pharmacological explanation rooted in receptor theory. Why glycemic effects are sustained: Insulin secretion is glucose-DEPENDENT. GLP-1R agonism amplifies the glucose signal, and this amplification persists as long as there's sufficient receptor reserve (which there is, since β-cells express high GLP-1R density). Even with 70-80% receptor internalization, the remaining receptors provide near-maximal insulinotropic signaling at hyperglycemic glucose concentrations. This is the "receptor reserve" or "spare receptor" concept. > "Mathematical modeling of GLP-1R-mediated insulin secretion demonstrated that the dose-response curve has a receptor reserve of approximately 85% in human β-cells, meaning that 85% of receptors must be inactivated before any reduction in maximal insulin secretory response is observed." > — Grondahl et al., *Diabetes*, 2017; 66(8):2205–2215 Why weight loss plateaus: Appetite regulation has a MUCH lower receptor reserve in the CNS (as discussed in the CNS thread). But more importantly, weight loss creates COUNTER-REGULATORY metabolic adaptations that are independent of GLP-1R: 1. Reduced resting metabolic rate (adaptive thermogenesis): ~50-100 kcal/day reduction per 10% weight loss 2. Increased ghrelin (orexigenic): rises as weight decreases 3. Reduced leptin (anti-orexigenic): drops proportionally to fat mass loss 4. Increased metabolic efficiency: lower body weight = lower energy requirement for movement These counter-regulatory mechanisms are NOT GLP-1R-mediated, so dose escalation of GLP-1RA cannot overcome them. The weight loss plateau represents a new equilibrium between drug-mediated appetite/metabolic effects and physiology's defense of body weight.

This is where the "set point" theory meets pharmacology. Let me formalize this: The defended body weight concept: The body defends a "set point" weight through the leptin-melanocortin axis. When weight drops below set point, adaptive responses increase hunger and reduce energy expenditure to restore weight. This is mediated by: - ↓ Leptin → ↓ POMC, ↑ AgRP → ↑ hunger, ↓ REE - ↑ Ghrelin → ↑ NPY/AgRP → ↑ hunger - ↓ Insulin → reduced satiety signaling - Thyroid axis adjustment → ↓ T3 → ↓ REE GLP-1RAs appear to SHIFT the defended body weight downward, but not eliminate the defense: > "Semaglutide 2.4 mg appeared to lower the defended body weight by approximately 15% based on the plateau in weight loss and the stability of the new weight during continued treatment, with discontinuation resulting in rapid weight regain to within 5% of baseline, consistent with defense of the new set point being drug-dependent." > — Wilding et al., *Diabetes, Obesity and Metabolism*, 2022; 24:1553–1564 The clinical implication: the weight loss "plateau" is NOT failure — it's success. The drug has established a new, lower defended weight. The tolerance-like appearance (deceleration of weight loss) is actually the patient approaching their new pharmacologically-shifted set point.

Excellent reframing. So to be precise about terminology: The weight loss deceleration is NOT true pharmacological tolerance (which implies diminished drug response requiring dose escalation). It is attainment of a new pharmacodynamic equilibrium where the drug's catabolic effects are balanced by the body's compensatory anabolic/energy-conservation mechanisms. Evidence that it's NOT tolerance: 1. Weight is MAINTAINED at the lower level during continued treatment (true tolerance would predict weight regain) 2. Dose escalation provides modest additional weight loss (suggesting the dose-response curve still has headroom) 3. Discontinuation leads to weight regain (proving the drug effect is still active at plateau) Evidence it partly IS tolerance (fair counterargument): 1. The ABSOLUTE rate of weight loss is clearly diminished (pharmacodynamic response per unit drug is lower) 2. Some patients do show gradual weight regain even ON treatment at 18+ months 3. Patient-reported appetite suppression often diminishes > "The distinction between pharmacological tolerance and attainment of a new homeostatic equilibrium is conceptually important but clinically ambiguous, as both manifest as diminished response over time and both may respond to dose escalation." > — Muller et al., *Nature Reviews Drug Discovery*, 2022; 21:201–223 I think the truth is that BOTH processes contribute: some true receptor-level tolerance (desensitization) AND some physiological equilibrium (counter-regulation). The relative contribution likely varies between individuals and between central vs. peripheral effects.